Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 490

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 490
---
 execution of the definitive agreement to exercise the option for the License Agreement, of which $40,000 was paid in cash and the remaining $130,000 was paid in 23,028 NLS Common Shares. In addition, Aexon will receive 15% of all proceeds earned by us in any future sub -licensingagreements. We must also make royalty payments to Aexon upon the occurrence of certain milestones. Such payments upon the occurrence of milestones contemplated in the License Agreement range from $100,000 to $300,000, in addition to percentage royalty payments ranging from 5% to 15% which may decrease or increase up to 30% if we challenge the validity of the patents under the agreement, depending on the result of 264 such challenge. Further, pursuant to the License Agreement, we agreed to pay Aexon a percentage of license fees, milestones and royalties received from sublicensees, ranging between 5% and 15% which may decrease or increase up to 30% if we challenge the validity of the patents under the agreement, depending on the result of such challenge. In January 2025 through July 2025, we paid $50,000 in consideration for 50% of the proof of concept first milestone under the License Agreement. Debt Conversion During the month of October 2024, we entered into Debt Forgiveness Agreements with certain lenders, including Alexander Zwyer, Ronald Hafner, Eric Konofal, Florence Allouche Aknin, Audrey Greenberg and Gian -MarcoRinaldi, or the Lenders, pursuant to which the Company issued an aggregate of 493,986 NLS Common Shares at a conversion price of $5.65 (rounded) per share, in full satisfaction of an aggregate amount of CHF 2,089,945 ($2,296,643) and $492,007 in loans and advances previously provided to the Company by the Lenders, or collectively, the Loan Agreements described under “— Shareholders and Officer and Director Loans” above. This conversion was facilitated through an ordinary capital increase, providing the necessary shares for the debt holders, and was recorded at fair market value with no gain or loss recognized in the statement of operations. October 2024 Financings On October 9, 2024, we entered into a securities purchase agreement with certain accredited investors, including Ronald Hafner. Under this agreement, we issued and sold 806,452 NLS Common Shares and warrants to purchase an additional